pili

« Hoʻi i ka Pipeline

Māhele:

yhan-logo-pūnaewele

ʻAno waiwai:

Immuno-Oncology

Kāhea hoa:

ʻO Yuhan Corporation kekahi o nā hui lāʻau lapaʻau Korea nui loa, i hoʻokumu ʻia ma mua o 80 mau makahiki i hala

Nā kikoʻī pili pili:

ʻO Joint Venture i kapa ʻia ʻo ImmuneOncia Therapeutics, LLC

Hoʻopaʻa ʻia i ka hoʻomohala ʻana a me ka hoʻolaha ʻana i ka nui o nā antibodies immune checkpoint no nā maʻi maʻi hematological a me nā ʻōpū paʻa


Māhele:

ʻAno waiwai:

Immuno-Oncology

Kāhea hoa:

ʻO Lee's Pharm kahi hui biopharma lehulehu me ka ʻoi aku o 20 mau makahiki o ka hana ma Kina a ke kūʻai aku nei i nā huahana 14 i ka PRC.

Nā kikoʻī pili pili:

Ua laikini ʻo Sorrento i nā kuleana kūʻokoʻa iā Lee's Pharm e hoʻomohala a kūʻai aku i ke kanaka anti-PD-L1 mAb STI-A1014 no ka mākeke Kina nui aʻe.


Māhele:

celularity-logo-pūnaewele

ʻAno waiwai:

Lapaʻau Cellular

Kāhea hoa:

ʻO Celularity kahi spin-off mai Celgene Corporation e kālele ana i nā lāʻau lapaʻau i loaʻa i ka placenta a me ke kaula-koko.

Nā kikoʻī pili pili:

Hoʻolilo Kaulike a me ka Lunamakaainana Papa


Māhele:

mabpharm-logo01

ʻAno waiwai:

Immuno-oncology

Kāhea hoa:

ʻO MABPHARM kahi hui biopharma e kālele ana i ka R&D a me ka hana ʻana i nā lāʻau lapaʻau hou a me "Biobetters" no ka maʻi kanesa a me nā maʻi autoimmune.

Nā kikoʻī pili pili:

He laikini kūʻokoʻa ko Sorrento e kūʻai aku i ʻehā Biobetters i hoʻopau i nā haʻawina Phase 3 ma Kina no nā mākeke ʻAmelika ʻAmelika, ʻEulopa a me Iapana.


Ma Sorrento, ʻimi mākou i nā pilina ikaika a me nā hui like ʻana ma ke ʻano he mea hoʻokele koʻikoʻi o kā mākou hoʻolālā e pana i nā palena o ka ʻepekema a hāʻawi i nā lāʻau hoʻololi ola i nā poʻe maʻi i hiki ai iā lākou ke ola olakino a hauʻoli.